08:45 AM EDT, 04/22/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Monday that it has selected a move-forward expansion dose for a mid-stage trial evaluating its IDE397 monotherapy in MTAP-deletion squamous non-small cell lung cancer, or NSCLC.

Squamous NSCLC has been identified as the most sensitive tumor type of IDE397 monotherapy, the company said.

There are more than 100,000 global annual incidence of MTAP-deletion squamous NSCLC, the company added.